touchONCOLOGY talks to Jeffrey S Weber from the Laura and Isaac Perlmutter Cancer Cente and NYU Langone Medical Center about the limitations of ipilimumab for the treatment of resected stage III melanoma and how the findings of the CheckMate238 trial can improve the safety profile of this patient population.
1. What are the limitations of ipilimumab as adjuvant therapy in patients with resected stage III melanoma? (0:11)
2. What is the current prognosis for patients with resected stage III or IV melanoma? (1:28)
3. What are the aims of the CheckMate 238 study? (2:51)
4. What have been the efficacy findings of the study to date? (3:31)
5. How does the safety profile of nivolumab compare to that of ipilimumab in this patient population? (4:36)
Speaker disclosures: Jeffrey S Weber has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018.
Read our Insight coverage here.
Share this Video
Related Videos In Melanoma
Georgina Long, ESMO 2022: Highlights in melanoma – SWOG S1801 trial investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma
Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss clinical trial highlights in melanoma presented at EMSO 2022. She highlights the SWOG S1801 trial, investigating neoadjuvant versus adjuvant pembrolizumab for resected stage III-IV melanoma, concluding use of a single-agent pembrolizumab, neoadjuvant therapy improves event-free survival compared to adjuvant therapy in high-risk resectable […]
Georgina Long, ESMO 2022: CheckMate 915 study – The use of ctDNA as a biomarker for predicting outcomes for adjuvant melanoma
In patients with resectable melanoma, circulating tumor DNA (ctDNA) detection post-resection may be useful to inform disease state and recurrence risk. Prof. Georgina Long (Melanoma Institute Australia, Wollstonecraft, Australia) joins touchONCOLOGY to discuss CheckMate 915 study and what it taught us about the use of nivolumab plus ipilumab in the adjuvant treatment of melanoma, and […]
Jason Luke, ESMO 2021: Efficacy and Safety Results from the KEYNOTE-716 Double-blind Phase III Trial
touchONCOLOGY joins Dr Jason Luke (UPMC Hillman Cancer Center, PA, USA) at ESMO 2021 to discuss the efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. Questions 1. Patients with high-risk stage II melanoma are at significant risk of recurrence after surgical resection – what treatment options do these patients currently have to […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!